Lonza Group AG (FRA:LO3)

Market Cap	40.25B -2.4%
Revenue (ttm)	7.01B -0.7%
Net Income	1.02B +49.2%
EPS	14.51 +51.5%
Shares Out	n/a
PE Ratio	39.49
Forward PE	27.77
Dividend	4.27 (0.72%)
Ex-Dividend Date	May 13, 2025

Volume	284
Average Volume	58
Open	625.60
Previous Close	607.60
Day's Range	593.00 - 625.60
52-Week Range	542.40 - 639.20
Beta	n/a
RSI	42.32
Earnings Date	Jan 28, 2026

About Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substanc...

• Industry: Chemicals and Allied Products
• Founded: 1897
• Employees: 19,299
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LO3

Financial Performance

In 2025, Lonza Group AG's revenue was 6.53 billion, a decrease of -0.65% compared to the previous year's 6.57 billion. Earnings were 949.00 million, an increase of 49.21%.

Financial numbers in CHF